Many studies have suggested that E3 ubiquitin ligases can behave as either oncogenes or tumour suppressor genes and, recently, it has become clear that the SOCS (suppressor of cytokine signalling) E3 ligases fit this mould. While most cancer-associated E3s regulate the cell cycle or DNA repair, the SOCS proteins inhibit growth factor responses by degrading signalling intermediates such as JAKs (Janus kinases) via the SOCS-box-associated ECS (Elongin-Cullin-SOCS) E3 ligase. Clinical studies have found that (epi)genetic (mutation or methylation) phenomena can occur in many solid tumours and a growing number of clinical findings reveal post-translational modifications that disrupt SOCS function in haematological malignancy. In the present review, we provide a summary of the functions of the SOCS E3s and propose the potential use of members of this family as diagnostic markers and therapeutic targets in cancer.
Introduction

Regulation of cytokine signalling
Cytokines are soluble glycoproteins which regulate the growth and differentiation of a variety of cells including immune and haematopoietic cells. Receptors of the cytokine superfamily do not possess intrinsic kinase activity and instead rely on intracellular kinases to transmit their signals. One such pathway involves the JAKs (Janus kinases) and STATs (signal transducers and activators of transcription) and is commonly known as the JAK/STAT signalling pathway [1] . Prolonged cytokine signalling can be detrimental; dysregulation of cytokine signalling pathways is associated with many diseases, including several cancers, disorders in haematopoiesis and autoimmune diseases. Therefore cytokine responses are stringently controlled by a number of regulatory processes. A key family involved in this regulation is the SOCS (suppressor of cytokine signalling) family [2, 3] .
SOCS proteins
The eight SOCS proteins {CIS [cytokine-inducible SH2 domain (Src homology 2 domain)-containing protein] and SOCS1-7} identified characteristically contain a central SH2 domain and a conserved ∼40-amino-acid C-terminal SOCS-box domain [4] . Only SOCS1 and SOCS3 possess a KIR (kinase inhibitory region) immediately upstream of the SH2 domain which is believed to enhance binding and inhibition of JAK activity [5, 6] . Functionally, SOCSs are thought to negatively regulate JAK/STAT signalling by either (i) binding directly to JAKs/cytokine receptors, (ii) competing with STATs for phosphorylated docking sites on receptors or (iii) targeting signalling intermediates to the ubiquitin proteasome pathway through ECS (Elongin-Cullin-SOCS) E3 ligase formation [7] .
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The importance of SOCS in regulating cytokine responses has emerged from socs −/− mice. socs1 −/− mice develop lymphoid atrophy and liver damage and die within 3 weeks of birth due to uncontrolled IFN-γ (interferon-γ ) signalling [8] . Although socs1 −/− mice with null mutations in Ifn-γ or stat6 rescue the socs1 −/− phenotype, these mice eventually succumb to a range of inflammatory diseases, including skin ulcers, granulomas and polycystic kidney disease, due to aberrant signalling of other inflammatory cytokines, including IL-4 (interleukin-4) and IL-6 [9, 10] . SOCS1 deficiency is therefore associated with a wide range of acute and chronic inflammatory disorders. socs2 −/− mice develop gigantism characterized by increased body weight, bone length and organ size, suggesting that SOCS2 is a key negative regulator of the GH (growth hormone)-STAT5b signalling pathway [11, 12] . Intriguingly, SOCS2 transgenic mice also display the same phenotype as socs2 −/− mice [13] . We and others have shown that this is likely to be a consequence of SOCS2's ability to down-regulate the expression of other SOCS proteins that normally inhibit GH signalling [14] . SOCS2 has also been associated with the regulation of IGF-1 (insulin-like growth factor-1), prolactin, IL-2, IL-3, EPO (erythropoietin), LIF (leukaemia inhibitory factor), EGF (epidermal growth factor), leptin and IFN-α signalling pathways, and SOCS2 is thought to play an important role in the central nervous system, metabolism and mammary gland development [15] .
Unlike SOCS1, SOCS3 only inhibits JAKs when bound to receptors, such as the LIF or IL-6 receptor through Tyr-759 [16] , the leptin receptor through Tyr-985 [17] and the EPOR (EPO receptor) through Tyr-401 [18] . socs3 −/− mice die embryonically due to placental defects [19] . This is thought to be a consequence of enhanced LIF activation and excessive trophoblast giant-cell differentiation as inactivation of the LIF receptor rescues the socs3 −/− phenotype [20] . SOCS3 deficiency, leading to sustained IL-6 activation of STAT3, also contributes to the progression of chronic inflammatory diseases, such as arthritis, Crohn's disease and inflammatory bowel disease [21, 22] . In support of this, a mutation in gp130 (glycoprotein 130) (Y759F), which renders SOCS3 [and SHP-2 (SH2 domain-containing protein tyrosine phosphatase 1)] incapable of binding, resulted in mice with gastric adenoma and arthritis. Similarly, periarticular injection of recombinant SOCS3 was found to reduce the severity of joint swelling in mice with collagen-induced arthritis [23] . Enhanced SOCS3 expression was found in T-cells of patients with atopic dermatitis, while the reduction of SOCS3 levels reduced the severity of allergic conjunctivitis [24, 25] . Abundant evidence therefore exists that SOCSs are key negative regulators of the inflammatory response and are essential in maintaining normal cellular homoeostasis. Given that >20% of all malignancies are initiated or exacerbated by inflammation, it is not surprising that SOCS proteins are now regarded as tumour suppressors [26, 27] .
SOCS as tumour suppressors
Tumour suppressor genes prevent the formation of tumour cells by enforcing anticancer mechanisms such as cell growth arrest, DNA repair and apoptosis. The loss of function of a tumour suppressor gene can increase the probability of the formation of a tumour. p53 and pRb (retinoblastoma family protein) are archetypal tumour suppressor proteins. p53 is involved in apoptosis and cell cycle regulation and is one of the most mutated genes in human cancers with the restoration of p53 function leading to the regression of tumours [28] . pRb prevents the replication of damaged DNA and is dysfunctional in many cancers [29] . The loss of pRb function leads to the overexpression of the mitotic checkpoint protein MAD2 (mitotic arrest-deficient protein 2), which in turn promotes aneuploidy, a hallmark of many cancers [30] .
Defects in JAK/STAT signalling pathways are associated with many cancers; therefore SOCS proteins play an important tumour suppressor role preventing the dysregulation of such pathways. In the present review, we will explore how aberrant SOCS expression and function leading to enhanced JAK/STAT signalling can occur by several mechanisms each of which will be discussed in relation to cancer formation.
Mutations/deletions
Classically, point mutations, deletions, rearrangements and duplications in tumour suppressor genes are frequently involved in malignant cell transformation. For instance, mutational inactivation of both Rb1 alleles is the primary molecular cause of retinoblastoma. Approx. 10% of retinoblastoma cases are inherited and are caused by germline transmission of one mutated Rb1 allele and loss of the remaining wild-type allele in somatic retinal cells [31] . Similarly, at least 29 different BRCA1 (breast-cancer susceptibility gene 1) germline mutations have been mapped that predispose women to breast and ovarian cancers [32] . In relation to SOCS, a biallelic mutation in SOCS1 resulting in a defective SOCS1 SOCS-box was observed in the primary mediastinal large B-cell lymphoma cell line, MedB-1 [33] . Similarly, in the primary Karpas 1106P lymphoma cell line, a large biallelic chromosome deletion on 16p13.13 which includes socs1 was observed, again resulting in constitutive JAK/STAT signalling [34] . Finally, socs1 mutations were also present in 8/19 laser-microdissected Hodgkin and Reed-Sternberg cells of classical Hodgkin lymphomas, which correlated with nuclear accumulation of pSTAT5 [35] . As stated, the SOCSbox enables SOCS1 to form a multi-subunit E3 ligase complex to target SOCS1-associated proteins to the ubiquitinproteasome pathway [36] . It is thought that impaired SOCS1-mediated JAK2 degradation results in sustained JAK2 activation and low turnover of JAK2 protein leading to lymphomas.
Methylation
DNA methylation involves the addition of a methyl group at position C-5 of the cytidine ring in the context of a CpG dinucleotide, often in gene promoter regions, leading to transcriptional silencing of that gene. Aberrant methylation is the best-studied epigenetic abnormality in tumorigenesis, and hypermethylation of tumour suppressor gene promoters including APC (adenomatous polyposis coli), p16, BRCA1, Rb and Mdm2 (murine double minute 2), is often associated with cancer development [37] . Similarly, IL-6, a pro-inflammatory cytokine, enhances and maintains hypermethylation of the p53 tumour suppressor gene and the hHR23B gene, a key component of the nucleotide excision repair promoter in the multiple myeloma cell line KAS-6/1 [38] . Conversely, IL-6 induced hypomethylation of EGFR (EGF receptor), leading to enhanced EGFR expression and growth of cholangiocarcinoma cells [39] . These results suggest that DNA hypo-and hyper-methylation are important mechanisms that could contribute to inflammation-associated tumorigenesis. Since SOCS proteins have recently been added to this list of tumour suppressors, a great deal of interest has focused on the methylation status of socs in human tumours. Aberrant methylation of socs1 CpG islands has been reported in lymph node metastasis, advanced human gastric carcinoma [40] , HCC (hepatocellular carcinoma) [41] , myeloma [42] and pancreatic [43] and breast carcinoma [44] where socs1 silencing in tumour cells is believed to enhance IL-6-mediated cell proliferation. In HCCs, appox. 65% of primary tumours showed abnormal socs1 methylation in exon 2 and restoration of SOCS1 expression suppressed cell growth and resulted in apoptosis [40] . Additionally, socs1 −/+ mice developed more severe liver fibrosis than wild-type littermates [45] . As well as hypermethylation, it has also been suggested that HCC resulting from HCV (hepatitis C virus) infection is a consequence of the viral core protein selectively suppressing socs1 gene expression in liver tissues [46] . The ability of HCV to modulate the tumour suppressor activity of SOCS1 or IFN responses may contribute to HCV pathogenesis. Likewise, SOCS3 is methylated in approx. 90% of head and neck squamous cell carcinoma samples, in HCC and in non-smallcell lung carcinomas [47] [48] [49] . The loss of SOCS3 expression is thought to confer a cell growth advantage and promote cell migration due to enhanced JAK/STAT and FAK (focal adhesion kinase) signalling respectively.
Aberrant SOCS phosphorylation associated with cancer development
While substantial evidence exists that silencing of the SOCS1 tumour suppressor protein is a major oncogenic factor, SOCS1 expression seems to be stabilized in some tumours. SOCS1 expression correlated with tumour invasion, thickness and stage in human melanoma [50] . Similarly, constitutive SOCS1 expression was observed in CML (chronic myeloid leukaemia) [51] and increased SOCS1, SOCS3 and CIS expressions were observed in situ in infiltrating breast ductal carcinomas [52] . Likewise, SOCS3 expression conferred a growth advantage in a human melanoma cell line and silencing of SOCS3 by siRNA (small interfering RNA) rendered these cells sensitive to the antiproliferative action of IL-6 [53] . The observation that SOCSs are stabilized in some tumours suggests that the degradative mechanisms that normally regulate SOCS turnover are defective.
As stated, SOCSs can also function as E3 ubiquitin ligases to accelerate the ubiquitination and degradation of SOCS binding partners [54] . Post-transitional modification of SOCS proteins may be a mechanism utilized by oncoproteins to circumvent their degradation by E3 ubiquitin ligases.
Serine phosphorylation can regulate the stability of SOCS1 and its capacity to interact with Elongin C. For example, vAbl-mediated phosphorylation of SOCS1 disrupts the interaction with the Elongin BC complex, thus blocking the SOCS1-mediated JAK degradation contributing to the transformational properties of v-Abl [55] . v-Abl does not directly phosphorylate SOCS1. Instead, v-Abl signalling induces several serine/threonine kinases, which could be responsible for the v-Abl-mediated phosphorylation of SOCS1. Obvious candidates are the Pim kinase family: Pim-1, Pim-2 and Pim-3 [56] . Mice deficient in all three family members have reduced body size and impaired proliferation of haematopoietic cells in response to growth factors [57] . Increased expression of Pim kinases has been associated with several cancers including lymphomas, prostate cancer and oral cancer [58] . Phosphorylation of SOCS1 by the Pim family of kinases has previously been shown to block the SOCS1-Elongin C interaction, and SOCS1 has been identified as a possible binding partner to Pim2 [59] . Pim1 and Pim2 are abundantly expressed in haematopoietic cells transformed by oncogenic kinases [60] . It has recently been demonstrated that Pim kinases play a key role in v-Abl transformation by regulating SOCS1 protein stability. It is now believed that Pim kinases inhibit the normal function of SOCS1 in v-Abl transformants by phosphorylating SOCS1, thereby preventing the negative regulation of signalling pathways downstream of v-Abl [61] .
The phenomenon of phosphorylation preventing the formation of an E3 ubiquitin ligase is not unique to SOCS1. Tyrosine phosphorylation of SOCS3 is important in regulating its stability. Phosphorylation of SOCS3 can occur at two tyrosine residues in the SOCS-box Tyr-204 and Tyr-221, thereby inhibiting the SOCS3-Elongin C interaction and promoting SOCS3 degradation. Furthermore, a SOCS3 mutant in which both tyrosine residues were mutated to phenylalanine delayed the turnover of SOCS3 and increased its half-life [62, 63] . In relation to transformation, SOCS3 protein is stabilized and tyrosine-phosphorylated in patients with MPDs (myeloproliferative disorders) such as PV (polycythaemia vera) [64] . Approx. 90% of PV patients possess a somatic mutation in JAK2 resulting in a valine-tophenylalanine substitution at position 617 (V617F) rendering JAK2 V617F constitutively active [65] [66] [67] [68] [69] . Since SOCS3 is a key regulator of the EPOR and the receptor-associated JAK2 kinase [70] , it is hypothesized that tyrosine-phosphorylated SOCS3 cannot regulate JAK2 V617F. Aberrant SOCS3 tyrosine phosphorylation by JAK2 V617F may inhibit the SOCS3-Elongin C interaction and in turn block SOCS3 E3 ligase activity. This may be a means by which JAK2 V617F bypasses the negative regulatory mechanisms of SOCS3.
Concluding remarks
While originally only considered as classical negative regulators of cytokine signalling, SOCS proteins also display tumour suppressor characteristics and are now becoming widely regarded as important tumour suppressor proteins. As previously discussed, loss of SOCS function promoting tumour formation can occur by several mechanisms including gene deletion, mutation or silencing due to hypermethylation. Post-transitional modifications such as aberrant phosphorylation may also contribute to loss of SOCS tumour-suppressive properties. In this instance, the loss of normal SOCS function requires particular consideration when investigating the progression of malignant diseases that are the result of oncogenic kinases. For example, overexpression of SOCS2 is found in patients in the most advanced stages of BCR (breakpoint cluster region)-Abl-positive CML and ALL (acute lymphocytic leukaemia) as well as BCR-Abl-positive cell lines [71] . Constitutive expression of SOCS1 and SOCS3 has also been associated with CML and may contribute to the progression of disease by conferring resistance on IFN therapy [72] . We have recently reported the aberrant phosphorylation of SOCS3 in PV patients homozygous for the JAK2 V617F mutation [64] . Oncogenic kinases may use post-transitional modification of SOCS proteins, such as aberrant phosphorylation, to prevent the negative regulation of pathways required for cell growth and proliferation while simultaneously sustaining the negative regulation of pathways important in cytokine therapy.
The inclusion of SOCS proteins in the ever-expanding group of tumour suppressor proteins will no doubt encourage the development of novel therapies which address the loss of normal SOCS function, such as gene and protein therapy, while the aberrant expression of SOCS proteins in some cancers may lead to their inclusion as prognostic markers of such malignancies.
